Solid dispersion of myeloid quinorm inhibitors and pharmaceutical compositions containing the same
A solid dispersion of 5-chloro-N-(3-cyclopropyl-5-{[(3R,5S)-dimethylpiperazine-1-yl]methyl}phenyl)-4-(6-methyl-1H-indole-3-yl)pyrimidine-2-amine with a hydrophilic polymer carrier addresses delivery challenges, significantly improving pharmacokinetic properties and therapeutic efficacy for treating acute myeloid leukemia.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- HANMI PHARM CO LTD
- Filing Date
- 2024-05-31
- Publication Date
- 2026-06-16
AI Technical Summary
Current formulations of 5-chloro-N-(3-cyclopropyl-5-{[(3R,5S)-dimethylpiperazine-1-yl]methyl}phenyl)-4-(6-methyl-1H-indole-3-yl)pyrimidine-2-amine, a potent inhibitor of myeloid kinases, face challenges in achieving effective and safe delivery for treating conditions like acute myeloid leukemia due to limitations in pharmacokinetic properties.
A solid dispersion of the compound is formulated with a hydrophilic polymer carrier, such as hydroxypropyl methylcellulose acetate succinate, using methods like spray drying, to enhance its pharmacokinetic properties, resulting in improved drug exposure and bioavailability.
The solid dispersion significantly increases maximum plasma concentration (Cmax) and area under the curve (AUC) by 2 to 3 times, enhancing the therapeutic efficacy of the compound in treating conditions like acute myeloid leukemia.
Smart Images
Figure 2026519563000001_ABST